5 questions about the FDA's fast-track push for psychedelic treatments
The Food and Drug Administration awarded priority review vouchers to three companies developing psychedelic-based treatments for mental health conditions -- two studying psilocybin for hard-to-treat depression and one studying methylone, an MDMA-related drug, for PTSD.
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
Michael
Veteran Owned and Operated Business
